SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (664)8/10/2004 12:24:51 PM
From: rkrw   of 1022
 
Correct, from abgx. Thanks for the pointer. An interesting program. Once/6 month injection.

Q2 CC:
Additional data were presented by Abgenix's technology
licensing partners, including encouraging Phase 1 data for
partner Pfizer, XenoMouse technology derived Anti CTLA 4
antibody in melanoma patients and data about AMG162 a
XenoMouse derived anti-body that's being developed by
Amgen for bone loss. Both of these partner antibodies may
result in future milestones and royalties to Abgenix.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News